What's Happening?
Neuromod Devices Ireland has announced the expansion of its tinnitus treatment device, Lenire, to Canada and Australia. This expansion will create 25 full-time roles across various sectors including engineering, operations, and sales. Lenire, which combines
tongue and auditory stimulation, is the first non-invasive bimodal neuromodulation device approved by the US FDA for tinnitus treatment. Clinical trials have shown its effectiveness, with significant improvements reported by patients. The device will be available in 17 hearing clinics in Canada starting March 2026, with plans to enter the Australian market later in the year.
Why It's Important?
The expansion of Lenire into new markets is significant as it addresses the needs of millions suffering from tinnitus, a condition affecting 15% of the global adult population. The creation of new jobs in high-skilled sectors also contributes to economic growth in the regions involved. The FDA approval and clinical success of Lenire highlight advancements in non-invasive medical treatments, potentially setting a precedent for future innovations in neuromodulation therapies.
What's Next?
Neuromod plans to continue expanding Lenire's availability in Europe, targeting the Netherlands and Portugal. The company will work with clinical partners to ensure the device's successful integration into new markets. As demand grows, further job creation and technological advancements in tinnitus treatment are anticipated.
